ALLO vs. AUPH, ELVN, ABCL, PAHC, VERV, COLL, NTLA, AKBA, AVDL, and RCUS
Should you be buying Allogene Therapeutics stock or one of its competitors? The main competitors of Allogene Therapeutics include Aurinia Pharmaceuticals (AUPH), Enliven Therapeutics (ELVN), AbCellera Biologics (ABCL), Phibro Animal Health (PAHC), Verve Therapeutics (VERV), Collegium Pharmaceutical (COLL), Intellia Therapeutics (NTLA), Akebia Therapeutics (AKBA), Avadel Pharmaceuticals (AVDL), and Arcus Biosciences (RCUS). These companies are all part of the "pharmaceutical products" industry.
Allogene Therapeutics vs. Its Competitors
Allogene Therapeutics (NASDAQ:ALLO) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, media sentiment, risk and dividends.
In the previous week, Aurinia Pharmaceuticals had 7 more articles in the media than Allogene Therapeutics. MarketBeat recorded 9 mentions for Aurinia Pharmaceuticals and 2 mentions for Allogene Therapeutics. Allogene Therapeutics' average media sentiment score of 0.93 beat Aurinia Pharmaceuticals' score of 0.65 indicating that Allogene Therapeutics is being referred to more favorably in the media.
Allogene Therapeutics currently has a consensus price target of $8.44, suggesting a potential upside of 615.63%. Aurinia Pharmaceuticals has a consensus price target of $11.50, suggesting a potential upside of 53.74%. Given Allogene Therapeutics' higher possible upside, research analysts clearly believe Allogene Therapeutics is more favorable than Aurinia Pharmaceuticals.
Aurinia Pharmaceuticals has higher revenue and earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
83.6% of Allogene Therapeutics shares are owned by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. 13.2% of Allogene Therapeutics shares are owned by insiders. Comparatively, 12.2% of Aurinia Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Aurinia Pharmaceuticals has a net margin of 16.11% compared to Allogene Therapeutics' net margin of 0.00%. Aurinia Pharmaceuticals' return on equity of 14.27% beat Allogene Therapeutics' return on equity.
Allogene Therapeutics has a beta of 0.31, indicating that its share price is 69% less volatile than the S&P 500. Comparatively, Aurinia Pharmaceuticals has a beta of 1.16, indicating that its share price is 16% more volatile than the S&P 500.
Summary
Aurinia Pharmaceuticals beats Allogene Therapeutics on 10 of the 16 factors compared between the two stocks.
Get Allogene Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALLO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ALLO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Allogene Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ALLO) was last updated on 7/1/2025 by MarketBeat.com Staff
